| 1 |
34419376 | Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. | 2022 Mar |
1 |
| 2 |
35443055 | MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. | 2022 Apr 20 |
2 |
| 3 |
35565194 | KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer. | 2022 Apr 20 |
2 |
| 4 |
33099543 | ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study. | 2021 |
1 |
| 5 |
34824550 | Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer via Integrated Bioinformatics Analysis. | 2021 |
1 |
| 6 |
31332704 | Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. | 2020 May |
1 |
| 7 |
32751518 | Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. | 2020 Jul 30 |
2 |
| 8 |
32753889 | Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC. | 2020 |
1 |
| 9 |
32891532 | Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. | 2020 Oct |
3 |
| 10 |
31597567 | Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. | 2019 Oct 10 |
1 |
| 11 |
31600989 | KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. | 2019 Oct 9 |
1 |
| 12 |
29089357 | Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. | 2018 Jan 15 |
1 |
| 13 |
30149143 | Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. | 2018 Nov |
1 |
| 14 |
30217639 | KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer. | 2018 Nov |
2 |
| 15 |
28455360 | Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. | 2017 Aug 15 |
5 |
| 16 |
29163686 | Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer. | 2017 Dec |
3 |
| 17 |
26740498 | Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. | 2016 Feb |
1 |
| 18 |
26353932 | Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. | 2015 Oct 6 |
1 |
| 19 |
26415993 | Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. | 2015 Nov |
1 |
| 20 |
26416458 | KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. | 2015 Oct 20 |
3 |
| 21 |
26471290 | Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. | 2015 Oct 6 |
1 |
| 22 |
24139827 | Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. | 2014 Jan |
3 |
| 23 |
24439569 | Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? | 2014 Mar |
1 |
| 24 |
24768329 | Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. | 2014 Jul |
1 |
| 25 |
25081901 | A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. | 2014 Nov |
2 |
| 26 |
23211422 | Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study. | 2013 Jan |
1 |
| 27 |
23787801 | KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. | 2013 Sep |
1 |
| 28 |
22139083 | A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. | 2012 Oct 18 |
2 |
| 29 |
22588152 | A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. | 2012 Jun |
1 |
| 30 |
21575522 | [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer]. | 2011 Mar |
1 |
| 31 |
19281127 | [K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer]. | 2009 Feb |
1 |